KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Goodwill & Intangibles (2020 - 2025)

Bionano Genomics' Goodwill & Intangibles history spans 6 years, with the latest figure at $7.0 million for Q2 2025.

  • For Q2 2025, Goodwill & Intangibles changed N/A year-over-year to $7.0 million; the TTM value through Jun 2025 reached $7.0 million, changed N/A, while the annual FY2024 figure was $9.7 million, N/A changed from the prior year.
  • Goodwill & Intangibles for Q2 2025 was $7.0 million at Bionano Genomics, down from $9.7 million in the prior quarter.
  • Across five years, Goodwill & Intangibles topped out at $118.4 million in Q4 2022 and bottomed at $1.3 million in Q2 2021.
  • The 5-year median for Goodwill & Intangibles is $16.8 million (2022), against an average of $33.0 million.
  • The largest annual shift saw Goodwill & Intangibles surged 3929.66% in 2022 before it plummeted 30.05% in 2023.
  • A 5-year view of Goodwill & Intangibles shows it stood at $83.0 million in 2021, then skyrocketed by 42.69% to $118.4 million in 2022, then plummeted by 68.29% to $37.6 million in 2023, then plummeted by 74.16% to $9.7 million in 2024, then dropped by 27.61% to $7.0 million in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Goodwill & Intangibles are $7.0 million (Q2 2025), $9.7 million (Q4 2024), and $11.0 million (Q3 2024).